CRISPR Therapeutics AG
CRSP
查看详细走势图
56.250USD
-0.430-0.76%
收盘 12/15, 16:00（美东）报价延迟15分钟
5.28B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.76%
5天
-1.94%
1月
+7.08%
6月
+36.00%
今年开始到现在
+42.91%
1年
+28.48%
查看详细走势图
TradingKey CRISPR Therapeutics AG股票评分
单位: USD 更新时间: 2025-12-15操作建议
CRISPR Therapeutics AG当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名77/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价78.43。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CRISPR Therapeutics AG评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
30
位分析师
买入
评级
78.427
目标均价
+36.73%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CRISPR Therapeutics AG亮点
亮点风险
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
业绩高增长
公司营业收入稳步增长，连续3年增长3014.69%
业绩增长期
公司处于发展阶段，最新年度总收入37.31M美元
估值合理
公司最新PE估值-10.15，处于3年历史合理位
机构加仓
最新机构持股79.52M股，环比增加0.09%
默里·斯塔尔持仓
明星投资者默里·斯塔尔持仓，最新持仓市值10.68K
CRISPR Therapeutics AG新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CRISPR Therapeutics AG简介
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
公司代码CRSP
公司CRISPR Therapeutics AG
CEOKulkarni (Samarth)
网址https://crisprtx.com/
常见问题
CRISPR Therapeutics AG(CRSP)的当前股价是多少？
CRISPR Therapeutics AG(CRSP)的当前股价是 56.250。
CRISPR Therapeutics AG的股票代码是什么？
CRISPR Therapeutics AG的股票代码是CRSP。
CRISPR Therapeutics AG股票的52周最高点是多少？
CRISPR Therapeutics AG股票的52周最高点是78.480。
CRISPR Therapeutics AG股票的52周最低点是多少？
CRISPR Therapeutics AG股票的52周最低点是30.040。
CRISPR Therapeutics AG的市值是多少？
CRISPR Therapeutics AG的市值是5.28B。
CRISPR Therapeutics AG的净利润是多少？
CRISPR Therapeutics AG的净利润为-366.25M。
现在CRISPR Therapeutics AG(CRSP)的股票是买入、持有还是卖出？
根据分析师评级，CRISPR Therapeutics AG(CRSP)的总体评级为买入，目标价格为78.427。
CRISPR Therapeutics AG(CRSP)股票的每股收益（EPS TTM）是多少
CRISPR Therapeutics AG(CRSP)股票的每股收益（EPS TTM）是-5.543。
相关品种
